KRT89P

Across TCGA pan-cancer cohorts, KRT89P RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of KRT89P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where KRT89P RNA is repressed in tumor relative to normal tissue. In most cancer types KRT89P is over-expressed in tumor, although a few such as THCA and STAD show the opposite, repressed pattern.

THCA, BLCA, and BRCA are the cancer types where KRT89P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT89P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.777	<.001	11	view →
BLCA	All	All	+0.172	.002	10	view →
BRCA	All	II,III,IV	+0.454	<.001	6	view →
LUAD	Female	All	+0.165	<.001	6	view →
UCEC	All	All	+0.090	.008	4	view →
STAD	All	All	−0.402	.016	3	view →
COAD	All	All	+0.174	.017	2	view →
CHOL	All	All	+0.124	.021	2	view →
READ	All	All	−0.087	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

KRT89P–THCA

Open the THCA breakdown →